

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Psychotropic Medications Polypharmacy Clinical Edit
<b>First Implementation Date:</b>	November 5, 2010
<b>Proposed Date:</b>	December 17, 2020
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate and prudent use psychotropic medications

**Why Issue Selected:** MO HealthNet will assess the usage of psychotropic agents in the pharmacy program with a primary goal of patient safety in regard to polypharmacy or use of more drugs than is medically necessary. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and, by using medical evidence guidelines, this clinical edit can flag potentially dangerous duplication within drug classes, dangerous drug interactions, or overmedication. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Psychotropic medications
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- **Demonstrated compliance to prescribed therapy (90 out of 120 days) for participants  $\geq$  18 years of age who are not enrolled in foster care OR**
- Participant  $\leq$  5 years of age: history of  $\leq$  3 different psychotropic medications in the past 60 days **OR**
- Participant  $\geq$  6 years of age: history of  $\leq$  5 different psychotropic medications in the past 60 days
- Documented diagnosis of a seizure disorder: all seizure medications are not counted in a participant's past history of psychotropic medications

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

6 months

DRAFT

## Appendix A – Agents in the Psychotropic Medications Polypharmacy Clinical Edit

Psychotropic Medications
ALPRAZOLAM
AMITRIPTYLINE HCL
AMITRIPTYLINE/CHLORDIAZEPOXIDE
AMOBARBITAL SODIUM
AMOXAPINE
<b>AMPHETAMINE</b>
<b>AMPHETAMINE SULFATE</b>
ARIPIPRAZOLE
ARIPIPRAZOLE LAUROXIL
ARMODAFINIL
<b>ASENAPINE</b>
ASENAPINE MALEATE
ATOMOXETINE HCL
BREXPIPRAZOLE
BRIVARACETAM
BUPROPION HBR
BUPROPION HCL
BUSPIRONE HCL
BUTABARBITAL SODIUM
CARBAMAZEPINE
CARIPRAZINE HCL
CHLORDIAZEPOXIDE HCL
CHLORDIAZEPOXIDE/CLIDINIUM BR
CHLORPROMAZINE HCL
CITALOPRAM HYDROBROMIDE
CLOBAZAM
CLOMIPRAMINE HCL
CLONAZEPAM
CLONIDINE HCL
CLORAZEPATE DIPOTASSIUM
CLOZAPINE
DESIPRAMINE HCL
DESVENLAFAXINE
DESVENLAFAXINE FUMARATE
DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HCL
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE/AMPHETAMINE
DIAZEPAM
DIVALPROEX SODIUM
DOXEPIN HCL
DULOXETINE HCL
ESCITALOPRAM OXALATE
ESLICARBAZEPINE ACETATE

Psychotropic Medication continued
ETHOSUXIMIDE
ETHOTOIN
EZOZABINE
FELBAMATE
FLUOXETINE HCL
FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL
FLUVOXAMINE MALEATE
FOSPHENYTOIN SODIUM
GABAPENTIN
GABAPENTIN ENACARBIL
<b>GABAPENTIN/LIDOCAINE</b>
GUANFACINE HCL
HALOPERIDOL
HALOPERIDOL DECANOATE
HALOPERIDOL LACTATE
ILOPERIDONE
IMIPRAMINE HCL
IMIPRAMINE PAMOATE
ISOCARBOXAZID
LACOSAMIDE
LAMOTRIGINE
LEVETIRACETAM
LEVETIRACETAM IN NACL (ISO-OS)
LEVOMILNACIPRAN HCL
LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE
LITHIUM CITRATE
LORAZEPAM
LORAZEPAM IN 5 % DEXTROSE
LORAZEPAM/0.9% SODIUM CHLORIDE
LOXAPINE
LOXAPINE SUCCINATE
<b>LUMATEPERONE TOSYLATE</b>
LURASIDONE HCL
MAPROTILINE HCL
MEPROBAMATE
METHAMPHETAMINE HCL
METHSUXIMIDE
METHYLPHENIDATE
METHYLPHENIDATE HCL
MIDAZOLAM
MIDAZOLAM HCL
<b>MILNACIPRAN HCL</b>

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

<b>Psychotropic Medication continued</b>
MIRTAZAPINE
MODAFINIL
MOLINDONE HCL
NEFAZODONE HCL
NORTRIPTYLINE HCL
OLANZAPINE
OLANZAPINE PAMOATE
OLANZAPINE/FLUOXETINE HCL
OXAZEPAM
OXCARBAZEPINE
PALIPERIDONE
PALIPERIDONE PALMITATE
PAROXETINE HCL
PAROXETINE MESYLATE
PENTOBARBITAL SODIUM
PERAMPANEL
PERPHENAZINE
PERPHENAZINE/AMITRIPTYLINE HCL
PHENELZINE SULFATE
PHENOBARBITAL
PHENOBARBITAL SODIUM
PHENOBARBITAL/0.9 % SOD CHLOR
PHENYTOIN
PHENYTOIN SODIUM
PHENYTOIN SODIUM EXTENDED
PIMAVANSERIN TARTRATE
PIMOZIDE
<b>PITOLISANT HCL</b>
PREGABALIN

<b>Psychotropic Medication continued</b>
PRIMIDONE
PROTRIPTYLINE HCL
QUETIAPINE FUMARATE
RISPERIDONE
RISPERIDONE MICROSPHERES
RUFINAMIDE
SECOBARBITAL SODIUM
SELEGILINE
SERTRALINE HCL
SODIUM OXYBATE
<b>SOLRIAMFETOL HCL</b>
STIRIPENTOL
THIORIDAZINE HCL
THIOTHIXENE
TIAGABINE HCL
TOPIRAMATE
TRANLYCYPROMINE SULFATE
TRAZODONE HCL
TRIFLUOPERAZINE HCL
TRIMIPRAMINE MALEATE
VALPROIC ACID
VALPROIC ACID (AS SODIUM SALT)
VENLAFAXINE HCL
VIGABATRIN
VILAZODONE HCL
VORTIOXETINE HYDROBROMIDE
ZIPRASIDONE HCL
ZIPRASIDONE MESYLATE
ZONISAMIDE

*SmartPA Clinical Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.